N
ACOR

Nuveen’s Acorda Therapeutics ACOR Stock Holding History

Nuveen’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,491
Closed -$167K – 3395
2020
Q1 		$167K Buy
1,491
+79
+6% +$15.6K ﹤0.01% 3021
2019
Q4 		$346K Sell
1,412
-93
-6% -$23.5K ﹤0.01% 2977
2019
Q3 		$518K Sell
1,505
-235
-14% -$128K ﹤0.01% 2937
2019
Q2 		$1.6M Buy
+1,740
New +$2.14M ﹤0.01% 2536
2013
Q3 		– Sell
-210
Closed -$832K – 1579
2013
Q2 		$832K Buy
+210
New +$865K 0.01% 1119

Other funds holding ACOR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen's ACOR Position: Q2 2020 in Review

Nuveen sold out of Acorda Therapeutics (ACOR) in Q2 2020, closing a stake of 1,491 shares — an estimated $167K sold.

Nuveen first reported a position in ACOR in Q2 2013 and held it in 5 quarters. The position peaked at $1.6M in Q2 2019. 79 funds tracked by Wall St. Rank hold ACOR as of Q2 2020.

  • Nuveen reported no remaining Acorda Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Nuveen sold 1,491 Acorda Therapeutics shares in Q2 2020, an estimated $167K.
  • Nuveen first reported a position in Acorda Therapeutics in Q2 2013 and held it in 5 quarters.
  • Nuveen's Acorda Therapeutics position peaked at $1.6M in Q2 2019.
  • 79 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2020.

Based on Nuveen's 13F filing for Q2 2020, filed 14 Aug 2020.